Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical therapy. Issue 4 (24th February 2013)
- Record Type:
- Journal Article
- Title:
- Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical therapy. Issue 4 (24th February 2013)
- Main Title:
- Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical therapy
- Authors:
- Hoenigl, Martin
Seeber, Katharina
Koidl, Christoph
Buzina, Walter
Wölfler, Albert
Duettmann, Wiebke
Wagner, Jasmin
Strenger, Volker
Krause, Robert - Abstract:
- <abstract abstract-type="main" id="myc12060-abs-0001"> <title>Summary</title> <p>Data on diagnostic performance of Galactomannan (GM) testing in patients under mould‐active regimens are limited. Whether sensitivity of GM testing for diagnosing breakthrough invasive aspergillosis (IA) is decreased under antifungal prophylaxis/therapy remains therefore a point of discussion. We retrospectively analysed GM test results in patients who were admitted with underlying haematological malignancies to two Divisions of the Medical University Hospital of Graz, Austria, between 2009 and 2012. Only cases of probable and proven IA that were diagnosed by other methods than GM testing were included (time of diagnosis = day 0). We compared GM results of patients with/without therapy/prophylaxis for the period of 2 weeks prior (week −2) until 3 weeks postdiagnosis. A total of 76 GM test results in nine patients were identified. Six patients had received antifungal therapy/prophylaxis from week −2, whereas three patients were treated with therapy from the time of diagnosis at week 0. GM testing was positive in 45/76 (59%) of samples. Sensitivity of GM testing for detection of proven or probable IA at week −1 and 0 was 77% and 79% in patients with mould‐active regimens. We conclude that GM testing might be a useful diagnostic method for breakthrough IA in patients receiving mould‐active prophylaxis/therapy.</p> </abstract>
- Is Part Of:
- Mycoses. Volume 56:Issue 4(2013)
- Journal:
- Mycoses
- Issue:
- Volume 56:Issue 4(2013)
- Issue Display:
- Volume 56, Issue 4 (2013)
- Year:
- 2013
- Volume:
- 56
- Issue:
- 4
- Issue Sort Value:
- 2013-0056-0004-0000
- Page Start:
- 471
- Page End:
- 476
- Publication Date:
- 2013-02-24
- Subjects:
- Pathogenic fungi -- Periodicals
Medical mycology -- Periodicals
616.969 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1111/myc.12060 ↗
- Languages:
- English
- ISSNs:
- 0933-7407
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5995.753000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4383.xml